DNLI
insider transactionsDenali Therapeutics Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-52.4K
0 buy · 52.4K sell
Net value · 365d
-$864.9K
$0 in · $864.9K out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
2
0 buy · 52.4K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
19.2K sh
Own New
-
Grant·A
Director
$0
6.4K sh
Own +60%
-
Grant·A
Director
$0
19.2K sh
Own New
-
Grant·A
Director
$0
6.4K sh
Own +26%
-
Grant·A
Director
$0
19.2K sh
Own New
-
Grant·A
Director
$0
6.4K sh
Own +20%
-
Grant·A
Director
$0
19.2K sh
Own New
-
Grant·A
Director
$0
6.4K sh
Own +42%
-
Grant·A
Director
$0
19.2K sh
Own New
-
Grant·A
Director
$0
6.4K sh
Own +23%
-
Grant·A
Director
$0
19.2K sh
Own New
-
Grant·A
Director
$0
6.4K sh
Own +40%
-
Grant·A
Director
$0
19.2K sh
Own New
-
Grant·A
Director
$0
6.4K sh
Own +25%
-
Sell·S
COFO and Secretary
$284.1K
17.2K sh · $16.50
Own -6%
-
Sell·S
Ryan J. Watts KEY
President and CEO
$580.8K
35.2K sh · $16.50
Own -11%
-
Grant·A
COFO and Secretary
$0
173.1K sh
Own New
-
Grant·A
COFO and Secretary
$0
57.7K sh
Own +24%
-
Grant·A
Ryan J. Watts KEY
President and CEO
$0
236.9K sh
Own New
-
Grant·A
Ryan J. Watts KEY
President and CEO
$0
79.0K sh
Own +31%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 3, 2026 | Timothy Van Hauwermeiren | Grant A | 19.2K | $0 |
| Jun 3, 2026 | Timothy Van Hauwermeiren | Grant A | 6.4K | $0 |
| Jun 3, 2026 | Nancy Thornberry | Grant A | 19.2K | $0 |
| Jun 3, 2026 | Nancy Thornberry | Grant A | 6.4K | $0 |
| Jun 3, 2026 | Steve E. Krognes | Grant A | 19.2K | $0 |
| Jun 3, 2026 | Steve E. Krognes | Grant A | 6.4K | $0 |
| Jun 3, 2026 | David P Schenkein | Grant A | 19.2K | $0 |
| Jun 3, 2026 | David P Schenkein | Grant A | 6.4K | $0 |
| Jun 3, 2026 | Peter S Klein | Grant A | 19.2K | $0 |
| Jun 3, 2026 | Peter S Klein | Grant A | 6.4K | $0 |
| Jun 3, 2026 | Jay T Flatley | Grant A | 19.2K | $0 |
| Jun 3, 2026 | Jay T Flatley | Grant A | 6.4K | $0 |
| Jun 3, 2026 | Jennifer E. Cook | Grant A | 19.2K | $0 |
| Jun 3, 2026 | Jennifer E. Cook | Grant A | 6.4K | $0 |
| Jan 6, 2026 | Alexander O. Schuth | Sell S | 17.2K | $284.1K |
| Jan 6, 2026 | Ryan J. Watts KEY | Sell S | 35.2K | $580.8K |
| Jan 3, 2026 | Alexander O. Schuth | Grant A | 173.1K | $0 |
| Jan 3, 2026 | Alexander O. Schuth | Grant A | 57.7K | $0 |
| Jan 3, 2026 | Ryan J. Watts KEY | Grant A | 236.9K | $0 |
| Jan 3, 2026 | Ryan J. Watts KEY | Grant A | 79.0K | $0 |
About DNLI insider trading
This page tracks insider transactions for Denali Therapeutics Inc. (DNLI) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.